Dupixent shows potential as a treatment for atopic dermatitis, alopecia and vitiligo, targeting shared immune pathways for ...

Apogee Therapeutics recently reported positive 16-week results from its APEX Phase 2 Part A trial, with APG777 meeting all primary and key secondary endpoints in moderate-to-severe atopic dermatitis ...

Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a Phase 3 study titled ‘A Phase 3 Multi-Center, ...

For patients with skin of color and atopic dermatitis (AD), lebrikizumab is efficacious and safe, according to a study ...

USA: Atopic eczema (AE), including AE severity, is linked with a decreasing lymphocyte count, regardless of the use of the ...

Dupilumab use for atopic dermatitis and other conditions was associated with an increased risk of incident psoriasis but not psoriatic arthritis.

Patients with moderate to severe and severe alopecia areata have a greater burden of comorbid atopic dermatitis than those with mild alopecia areata.

Corvus Pharmaceuticals Inc. (($CRVS)) has held its Q2 earnings call. Read on for the main highlights of the call. Corvus ...

Answer: Atopic dermatitis is a very common skin disease found in both adults and children. In fact, up to 10 to 20 percent of the population at some point suffers from atopic dermatitis.

The current study, which was published in Archives of Dermatological Research in December 2017, included 50 patients with atopic dermatitis who met the UK Diagnostic Criteria for Atopic Dermatitis ...